Nyrada Trial Advances As Dosed Patients Rise And Site Network Expands
NYR: $0.460 -6.12% · MC: $133M
Nyrada says five patients have now been dosed in its PROTECT-MI Phase IIa trial, up from three at its previous update, with five sites active and three more expected to open by the end of November. The company is targeting final patient dosing in mid-2027 and preliminary results in the second half of 2027, while its US drug application submission remains targeted for the first half of 2027. Separately, Nyrada has issued the CDIs and attaching options associated with its recent capital raising.

Comments